The Six Winning Projects of the 12 th Edition of the IBSA Foundation Fellowships have been Awarded and the 2025 Call is Now Open
Research means investing in the future. This is the guiding principle behind the IBSA Foundation Fellowships programme, which for over a decade has supported talented researchers under 40 from universities and research institutions around the world. The programme awards grants to promote innovative and potentially groundbreaking projects in lesser-explored scientific fields; a constantly growing success, also confirmed by the 2024 edition, which marked a new record, with 259 applications across five scientific areas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522244202/en/
The Award Ceremony of the 12th edition of the IBSA Foundation Fellowship
The € 32,000 fellowships were awarded to research projects in five scientific areas: dermatology, endocrinology, fertility/urology, pain medicine/orthopaedics/rheumatology and healthy aging/regenerative medicine. In particular, this latter category has attracted growing interest over time, recording the highest number of applications this year: 89 projects out of a total of 259.
The winners of the 2024 edition are:
- Masami Ando Kuri, Wellcome Sanger Institute, Cellular genetics, Haniffa Lab, Cambridge, UK – Scientific area: dermatology
- Enchen Zhou, University of California San Diego, Christopher Glass Laboratory, US – Scientific area: endocrinology
- Ilaria Chiaradia, Charles Darwin Department of Biology and Biotechnology, Sapienza University of Rome, Italy – Scientific area: fertility/urology
- Prach Techameena,Karolinska Institutet, Neurobiology of Pain & Therapeutics, Saida Hadjab Group, Stockholm, Sweden – Scientific area: pain medicine / orthopaedics / rheumatology
- Sergio Pérez Diaz,Karolinska Institutet, Division of Clinical Physiology, Laboratory of Medicine Department, Stockholm, Sweden – Scientific area: healthy aging / regenerative medicine
- Vanessa López Polo,University of California San Francisco, Cardiovascular Research Institute, US – Scientific area: healthy aging/regenerative medicine
“Supporting the talent of young researchers represents for IBSA Foundation a strategic investment, driving scientific progress and fostering a society that is more aware and better equipped to face future challenges. In a context where access to a scientific career is increasingly complex, our Fellowships serve as a tangible tool to support young researchers at a difficult time, promoting merit and innovation”, statedSilvia Misiti, Director of IBSA Foundation for scientific research.
Since its launch in 2012, the IBSA Foundation Fellowships have attracted increasing interest, with 1,645 projects from 60 countries. Over twelve editions, 58 projects have been funded, totalling € 1.6 million.
A particularly noteworthy statistic is the high number of submissions from female researchers: 1,041 out of 1,645 applications, which testifies to their increasingly central role in international scientific research.
At the Milan (Italy) event, IBSA Foundation announced the opening of the 2025 call. Like in 2024, the new edition will award six € 32,000 grants and will welcome projects in five areas: dermatology, endocrinology, fertility/urology, pain medicine/orthopaedics/rheumatology and healthy ageing/regenerative medicine. The sixth scholarship will be assigned to the category that receives the highest number of applications.
From this year, the IBSA Foundation Research Equity Prize will also be introduced: worth € 5,000, the prize will be awarded to the best scientific project developed in a laboratory, research institute or university based in a developing country.
Researchers wishing to apply can submit their proposals by January 31, 2026, through the platform.
About IBSA |
IBSA (Institut Biochimique SA) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA will celebrate the 40th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has transformed the company into a multinational corporation employing over 2,300 personnel worldwide. IBSA’s growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people. |
About IBSA Foundation for scientific research |
Established in 2012 in Lugano by the pharmaceutical company IBSA (Institut Biochimique SA), IBSA Foundation for scientific research is the main promoter of IBSA Group’s social responsibility activities.
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20250522244202/en/
Contacts
For further information:
furrerhugi – Chérine Gurtner, Senior Consultant
cherine.gurtner@furrerhugi.ch
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Perma-Pipe International Holdings, Inc. Announces New Contract Award in Qatar27.5.2025 22:48:00 EEST | Press release
Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) today announced that it has received its first project award to be executed in Qatar since the announcement of the intent to mobilize there. The project will be for USD $2.4 million and will utilize Perma-Pipe’s fabrication capabilities and the XTRU-THERM® insulation system, a spray-applied polyurethane foam jacketed with a high-density polyethylene casing. Adham Sharkawy, Senior Vice President of Perma-Pipe’s MENA region, remarked, “In response to this important award, we will begin executing the project from a temporary facility in Doha, ensuring timely delivery and uninterrupted service to our client. Simultaneously, we are advancing the construction of our permanent facility in Qatar, which will serve as a long-term base for our regional operations. We are deeply grateful to our customers for their continued trust and confidence in Perma-Pipe’s capabilities.” Saleh Sagr, President, commented, “Expanding in Doha has been an impo
Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba27.5.2025 18:46:00 EEST | Press release
Galderma Group AG (SWX:GALD): Ad hoc announcement pursuant to Art. 53 LR Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild offering of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (“ADIA”) and Auba Investment Pte. Ltd. (“Auba”) announced today The repurchased shares will be held in treasury and financed by existing liquidity at hand Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it intends to repurchase approximately 2.4 million Galderma shares in the context of an accelerated bookbuilding offering (“ABO”) of approximately 16.7 million Galderma shares (approximately 7% of Galderma’s share capital) by EQT, ADIA and Auba. Galderma will participate in the ABO at the same price per share which will be determined in the bookbuilding. The repurchased shares will be financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to de
New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration27.5.2025 18:44:00 EEST | Press release
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister’s visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527294947/en/ Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong,
LambdaTest Introduces Automation MCP Server to Revolutionize Test Failure Triaging27.5.2025 18:00:00 EEST | Press release
LambdaTest, a unified agentic AI and cloud engineering platform, has announced the launch of its Automation MCP Server, a breakthrough solution designed to simplify and accelerate the process of triaging test failures. By enabling direct integration between AI assistants and LambdaTest’s test execution data, the Automation MCP Server empowers developers and QA engineers to investigate and resolve issues faster, without leaving their integrated development environment (IDE). The Automation MCP Server offers a seamless interface within the IDE, allowing users to access and analyze real-time test data with ease. With intelligent root cause analysis, the MCP server can quickly identify the underlying reasons for test failures and take immediate action to fix the underlying code. This results in fewer debugging cycles and faster release times. The server also enhances automated testing workflows by enabling the generation of new test cases using real execution data. Developers can leverage
Rigaku Completes New Building at Yamanashi Plant27.5.2025 17:00:00 EEST | Press release
Rigaku Corporation, a global solution partner in X-ray analytical technologies and a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; hereinafter “Rigaku”) completed an additional manufacturing building (hereinafter “the New Building”) at Yamanashi Plant, Rigaku’s main production facility. The facility was established to serve as the center of Rigaku’s production framework, in anticipation of global business growth and expansion in product demand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527974928/en/ Exterior view of the New Building, Yamanashi Plant Doubling of production capacity: a strategic base to support Rigaku’s growth Demand for X-ray analytical solutions has soared in recent years, both in Japan and worldwide. To respond to growing demand, Rigaku implemented this expansion with two key objectives in mind. One objective is to further reinforce the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom